Cormorant Asset Management, LP Atea Pharmaceuticals, Inc. Transaction History

Cormorant Asset Management, LP

  • $1.43 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$5.5 - $9.19 $727,435 - $1.22 Million
-132,261 Reduced 7.88%
1,547,181 $11.2 Million
Q4 2021

Feb 14, 2022
SELL
$7.67 - $44.59 $24.9 Million - $145 Million
-3,249,314 Reduced 65.93%
1,679,442 $15 Million
Q3 2021

Nov 15, 2021
SELL
$21.33 - $35.06 $31.6 Million - $52 Million
-1,482,599 Reduced 23.12%
4,928,756 $173 Million
Q4 2020

Feb 16, 2021
BUY
$26.36 - $41.78 $169 Million - $268 Million
6,411,355 New
6,411,355 $260 Million

Others Institutions Holding AVIR

# of Institutions
112
Shares Held
52.4M
Call Options Held
900
Put Options Held
126K
View Full List

About Atea Pharmaceuticals, Inc.

AVIR Quotes by TradingView
  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $281M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email